Battle Lines Have Been Drawn: Saving 340B Discounts
July 13, 2021
Ronald Hirsch, MD | Knicole Emanuel Esq. | David Glaser, Esq. | Andrew Markiewitz, MD | Matthew Albright | Maureen Testoni, JD
Six major U.S. drug manufacturers are refusing to provide 340B discount pricing for outpatient drugs sold to safety-net hospitals, community health centers, and public health clinics when those drugs are dispensed in community pharmacies.
Will it take an act of Congress to intervene in this ongoing battle to restore 340B discounts and refund overcharges? Maureen Testoni, J.D., President and CEO of 340B Health, will bring us up to speed on this rapidly developing situation during the next live edition of Monitor Mondays.
Other segments to be featured during the live broadcast include the following:
Monday Rounds: Ronald Hirsch, MD, vice president of R1 RCM, will return to make his Monday Rounds with another installment of his popular segment.
RAC Report: Healthcare attorney Knicole Emanuel, a partner at the law firm of Practus, will file the Monitor Mondays RAC Report.
Risky Business: Healthcare attorney David Glaser, shareholder in the law offices of Fredrikson & Bryon, will join the broadcast with his trademark segment, reporting on legal implications facing healthcare providers.
Legislative Update: Former Centers for Medicare & Medicaid Services (CMS) official Matthew Albright, now chief legislative affairs officer for Zelis, will report on the latest healthcare regulatory news coming out of Washington, D.C.
Billing Code 44: Physician advisor Andrew Markiewitz, MD will return to the broadcast to report on why getting Medicare inpatients into the correct status creates an administrative wrinkle: the dreaded billing Code 44.